The global neuroendocrine carcinoma treatment market was valued US$ 1.7 Bn in 2022, and is expected to exhibit a CAGR of 8% during the forecast period (2019 – 2029).Prominently driven by collaborative strategies for speedy research of drugs for neuroendocrine carcinoma treatment, the market is set for an impressive.
MHRA approves Pluvicto® and Locametz® for prostate cancer europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.